The" opiate receptor " has become a well-accepted entity, stimulating the search for an endogenous agonist. This has successfully revealed several different endogenous peptide opiates whose physiological role is under intense investigation, contributing to our understanding of pain and of opiate tolerance and dependence. A review of the current literuture is presented.
Major discoveries have recently been made in the pharmacology of the opiate narcotic analgesics. These developments are of interest to anaesthetists and could hold fruitful implications for future anaesthetic practice.
THE OPIATE RECEPTOR
A. H. Beckett appears to have been the first to postulate the existence of an "opiate receptor" to which classical receptor theory could be applied (Beckett and Casy 1954) , describing in considerable detail the likely structural characteristics of such a receptor.
I t was not until 1971 that Goldstein and his colleagues demonstrated saturable stereospecific binding of levorphanol to membrane fractions of mouse brain (Goldstein, Lowney and Pal 1971) . They suggested that the material responsible for this stereospecific binding might be the" opiate receptor ". Highly stereospecific binding of labelled opiates to brain tissue has subsequently been independently demonstrated in numerous studies (l{lee and Streaty 1974 , Lee ct al. 1973 , Lowney et al. 1974 , Pert and Snyder 1973a , Simon, Hiller and Edelman 1973 , Terenius 1973 a and b, \\Tong and Horng 1973 .
This does not itself necessitate that the opiatebinding-site combination is biologically active. To further test this hypothesis, Pert and Snyder (1973b) have studied a wide range of opiates and demonstrated a close correlation between their pharmacological potency as agonist or antagonist and their affinity for naloxonebinding sites on neuronal membranes. A large number of non-opiate drugs were also tested and none were found to have any affinity for the " receptor" in concentrations up to 0·1 mM.
Cerebroside sulphates have been identified in nerve membranes (Johnston and Roots 1972) and nerve endings within the central nervous system (A vrova, Chenykaeva and Obukhova 1973) . These molecular structures have been shown to bind to opiate molecules with high affinity in stereospecific binding (Loh et al. 1974) .
They also fulfil the requisites (Loh et al. 1975) postulated by Beckett (1954) for the opiate receptor. A partially purified " opiate receptor " from mouse brain has been shown to contain cerebroside sulphate (Loh et al. 1975) . and it is conjectured that such molecules may be identical with the " opiate receptor" itself.
EXDOGENOUS OPIATES
The existence of " opiate receptors " is now widely acknowledged (Goldstein 1974, Snyder and Matthysse 1975) . This has prompted the further conjecture that these do not exist by chance or in isolation, but that there may be an endogenous opiate, possibly functioning in some physiological neurotransmitter or neuromodulator system (Collier 1973 , Goldstein 1975 , Hughes 1975 ).
The Enkephalins
1Iorphine has been shown to inhibit neurallyevoked contractions of mouse vas deferens and guinea-pig myenteric plexus by an action at stereospecific receptor sites Leslie 1974, Kosterlitz, Lord and Watt 1972) .
Hughes has described the extraction and purification of a low molecular weight peptide from rabbit, guinea-pig, rat and pig brains Anaesthesia and Intensive Care, Vol. V, No. 2, May, 1977 (Hughes 1975) . This peptide inhibited neurallyevoked contractions of mouse vas deferens and guinea-pig myenteric plexus and the effect was readily reversed by naloxone and other opiate receptor antagonists. The distribution of this material throughout the brain was not uniform, maximal concentrations being found in the striatum, thalamus, pons and medulla. This distribution pattern corresponded well with that described in studies of "opiate receptor" distribution within the brain (Hiller, Pearson and Simon 1973, Kuhar, Pert and Snyder 1973) .
Hughes' group in Aberdeen named the newlydiscovered peptide "enkephalin" , and conjectured (Kosterlitz and Hughes 1975) that enkephalin functioned as an inhibitor by either post-synaptic or pre-synaptic inhibition or by inhibitory modulation.
Structural analysis by mass 3pectrometry revealed that enkephalin was composed of two pentapeptides: H-Tyrosine-Glycine-Glycine -Phenylalanine-Methionine-OH (Metenkephalin) and H-Tyrosine-Glycine-Glycine-Phenylalanine-Leucine-OH (Leuenkephalin), . Porcine enkephalin comprised these two in the ratio 3 : l. Each component had potent agonist activity in the mouse vas deferens and guinea-pig ileum preparations, Met-enkephalin being of higher potency than Leu-enkephalin. The action of each component was readily antagonized by naloxone. Both pentapeptides were synthesized and the synthetic molecules shown to be physicochemically identical with natural enkephalin.
Cross tolerance has been demonstrated between morphine and Met-enkephalin in morphine-tolerant animal preparations (Waterfield, Hughes and Kosterlitz 1976) .
Both pentapeptides have been shown to induce profound analgesia when administered to rats via a permanently indwelling cannula in the lateral ventricle (Belluzzi et al. 1976) .
The in vitro affinity of Met-and Leuenkephalin for rat brain opiate receptors has been shown to be 1/2 and 1/7 the affinity of morphine (Chang et al. 1976 ). However, the same workers found that on microinjection into the peri-aquaductal grey matter in the intact animal, high doses were required to produce only a very evanescent analgesia and stuperous immobility. They conjectured that this resulted from rapid enzyme degradation, suggesting that this may present a major problem in the development of synthetic peptide opiates for exogenous administration. Anaesthesia and Intensive Care, Vol. V, No. 2, May, 1977 American workers independently isolated a "morphine-like factor" from rat and calf brains (Pasternak, Goodman and Snyder 1975) , and showed that its distribution throughout the brain correlated well with that of the" opiate receptor ". They have since isolated and identified Met-and Leu-enkephalin from bovine brain (Simantov and Snyder 1976 a and b) . In this species, in contrast to pigs, Leu-enkephalin predominates in the ratio of 4 : l.
Alexander Gero has criticized the work on enkephalin on the grounds that the pentapeptides do not influence the rate of hydrolysis by human serum esterase, as do exogenous opiate agonists and antagonists Capetola 1975, Gero 1976) . He suggests that enkephalin may be only the prosthetic group for the true endogenous opiate. Wahlstrom (1974, 1975a) have described the isolation of an endogenous " morphine-like factor" with a molecular weight around 1,000 derived from extracts of rat, rabbit and calf brains. They have also isolated a similar morphine-like agonist for rat brain opiate receptors from human cerebro-spinal fluid (Terenius and Wahlstrom 1975b) . This factor may be identical with enkephalin.
Morphine-like factor

Pituitary peptide
A further peptide-like substance with opiate activity has been isolated from bovine and porcine pituitary extracts ). This peptide is of higher molecular weight than enkephalin and appears structurally similar to the known hypothalamic releasing and release-inhibiting factors .
~ Endorphin
During the isolation of melanotropins from camel pituitary glands, a 31 amino acid peptide was obtained and found to possess potent opiate agonist activity (Li and Chung 1976) . Structural analysis of this peptide revealed the five NH 2 -terminal amino acid residues to be identical with Met-enkephalin. It was also noted that this newly-discovered peptide constituted amino acids 61-91 of ~ lipotropin, the precursor of ~-melanocyte-stimulating hormone (~-MSH). Further investigation revealed that ~ lipotropin itself had no opiate activity, but that such opiate activity was generated by releasing amino acids 61-91 (Cox, Goldstein and Li 1976) . Opiate activity appeared to require a free Tyrosine in position 61, Met-enkephalin being amino acids 61-65 (Horn and Rogers 1976) .
The 31 amino acid peptide has been syn thesized and named " ~ endorphin" (Loh et al. 1976) .
In contrast to the enkephalins, it was a very potent analgesic when administered intracerebrally to rats, being IS-33 times more potent than morphine and with the analgesic effect lasting about 90 minutes. This effect was reversible with naloxone. Continuous administration of ~ endorphin for 70 hours resulted on cessation in typical signs of opiate withdrawal. ~ endorphin has also been isolated from porcine pituitary and its affinity for opiate receptors independently demonstrated (Bradbury et al. 1976) . It is described by these workers as the "C-fragment of lipotropin". They found its analgesic potency when injected via intraventricular cannulas in cats to be 100-200 times that of morphine (Feldberg and Smyth 1976) .
It is postulated that ~ lipotropin may be the common precursor of hoth ~-MSH and a whole family of endogenous peptide opiates (I{lee and Nirenberg 1976).
Anodynin
A peripherally-located small peptide opiate has also now been isolated from human blood (Pert, Pert and Tallman 1976) . Its structural formula is unknown but it differs chromatographically from the cnkephalins and has been named "anodynin". Injected into rat peria(luaductal grey matter it also produced profound analgesia lasting morc than an hour. This analgesia was readily reversed by naloxone. Lcvels of anodynin in the serum of hypophysectomized rats fcll to less than 5% of those found in controls. It is conjectured that anodynin may be an endogenous opiate released from the pituitary to act on peripheral opiate receptors. It is, however, a small lipophyllic molecule that may be able to penetrate the blood-brain barrier and produce centrallymediated effects as well.
H. Synthetic H cptape ptide
Goldstein and his colleagues, working from the theoretical structural criteria for opiate activity, have synthesized a linear heptapeptide : H -Tyrosine -Glycine -Glycine -Glycine -Lysine -"Methionine -Glycine -OH (Goldstein, Goldstein and Cox 197.5) . It has weak but definite opiate agonist activity that is reversed by' naloxone.
CENTRAL PAIN-SuPPRESSION SYSTEM
Liebeskind and his colleagues have suggested that endogenous opiates may function in a central pain-suppression system as either neurotransmitters or neuromodulators, the familiar exogenous opiates being effective because they activate such a system (Liebeskind, Mayer and Akil 1974) . This system might account for analgesia produced by electrical cerebral stimulation (Liebeskind et al. 1973) .
If this hypothesis were correct, a pure opiate receptor-antagonist such as naloxone might be expected to block the activation of the system. The experimental evidence is at present unclear.
Naloxone has been shown to lower the" pain threshold" in mice (Jacobs, Tremhlay and Colombel1974) . It has also been demonstrated to block analgesia produced by electrical stimulation of peri-aquaductal grey matter in rats (Akil, :\Iayer and Liebeskind 1972) and to suppress appetitive behaviour in rats (Holtzman 1974 (Holtzman , 1975 . In addition, it has been shown to antagonize acupuncture analgesia in man (l\Iayer et al. 1976) .
It is also of interest that Terenius and Wahlstrom assayed the titres of " morphine-like factor" in the cerebro-spinal fluid of eight patients suffering from trigeminal neuralgia and found it to be less than half that found in another group of patients suffering from a variety of painless neurological conditions (Terenius and Wahlstrom 1975b) .
On the other hand, Goldstein failed to demonstrate any effect by naloxone on the shock escape threshold in rats , and Yaksh was unable to antagonize with naloxone the elevated nociceptive thresr,olds in rats submitted to electrical stimulation of the mesencephalic grey matter (Yaksh, Young and Rudy 1976) .
OPIATES AND THE PROSTAGLANDINS
The action of opiates has been linked to the prostaglandins.
Collier, in work with homogenized rat brains, showed that E prostaglandin activated adenyl cyclase, leading to the production of cyclic A:\IP (c-A~lP), and that morphine was a potent blocker of this activation, although it did not affect the background levels of c-AMP itself (Collier and Roy 197.5, Roy and Collier 1975) .
This finding has been confirmed by work with tumour cell cultures. A neuroblastoma-glioma hybrid cell line was shown to contain about Anaesthesia and Intellsive Care, Vol. V , No. 2, c1Iay, 1.977 300,000 opiate receptors per cell (Klee and Nirenberg 1974) . Morphine inhibited the activation by adenyl cyclase of c-AMP in a homogenate of these cells (Sharma, Nirenberg and Klee 1975) .
A similar effect in intact hybrid cells has been reported by German researchers (Traber, Gullis and .
The effects of Met-and Leu-enkephalin on adenyl cyclase activity in hybrid cell culture have now been tested and they have been found to be potent, receptor-mediated inhibitors of adenyl cyclase in these cells (Klee and Nirenberg 1976) . Met-enkephalin was 100 and Leuenkephalin 25 times more potent than morphine. The inhibition of adenyl cyclase induced by these agents was completely reversed by naloxone.
It is suggested that there may be two interrelated receptor sites embedded in the cell membrane, and linked through the membrane to the adenyl cyclase system on its inner surface.
It is of interest that (3-MSH, derived from ~ lipotropin, is an activator of adenyl cyclase (Braun, Hechter and Li 1970) . ~ lipotropin may therefore be a precursor of both an activator ((3-MSH) and inhibitors (peptide opiates) of the same enzyme, the different molecules being recognized by different receptors on the same or on different cells (Klee and Nirenberg 1976) . These workers conjecture that the opiates may be general desensitizers of many different receptors which all activate adenyl cyclase within the same cell.
TOLERANCE AND DEPENDENCE
Collier has postulated that the morphineabstinence syndrome in dependent animals may result directly from increased c-AMP activity in morphine-sensitive cells (Collier and Francis 1975) . Prolonged suppression of adenyl cyclase by the opiate may result in a compensatory increase in available adenyl cyclase, resulting in turn in tolerance to the opiate. When opiate levels subsequently dropped, the high levels of now unsuppressed adenyl cyclase would lead to a large increase in c-AMP activity (Collier et al. 1975, Roy and .
A phosphodiesterase inhibitor would be expected to increase c-AMP activity and precipitate or worsen the morphine-abstinence syndrome in dependent animals, and a phosphodiesterase stimulator to have the opposite effect. This has been demonstrated in rats (Collier and Francis 1975) . The morphine- Anaesthesia and Intensive Care, Vol. V, No. 2, May, 1977 abstinence syndrome could also be precipitated in these animals by the intra-ventricular injection of c-AMP.
In rats who had received no opiate whatsoever, a potent centrally-acting phosphodiesterase inhibitor produced a state in which a quasimorphine abstinence syndrome, indistinguishable from the true morphine abstinence syndrome, was precipitated by a small dose of naloxone (Francis et al. 1975 ).
Snyder also demonstrated that although the opiate receptor site was single, . it appeared to fluctuate between two forms, one favouring agonist and the other antagonist binding (Pert and Snyder 1974 , Wilson, Pasternak and Snyder 1975 . A critical factor determining the conformation of the receptors was the sodium ion activity at the receptor site. The usual form of the receptor was the antagonist conformation associated with high sodium ion activity. The agonist conformation required low sodium ion activity. Snyder suggests that these two forms of the receptor may also be involved in the development of tolerance, long-continued exposure to opiates rendering the receptor less susceptible to change from the usual antagonist-binding form to the agonist-binding form. More agonist would thus be required to produce the same effect. Consistent with this hypothesis is the observation that dependent animals have increased sensitivity to opiate antagonists (Snyder 1975) . CONCLUSION Some important discoveries have been made in our understanding of the opiates. These discoveries have prompted us to ask new and interesting questions regarding the action of old and familiar drugs.
There are exciting prospects for significant developments in our understanding and management of pain, including the possibility that stimulation-induced analgesia, including acupuncture analgesia, may result at least in part from the release of an endogenous agonist for the opiate receptor.
We are also gaining a clearer understanding of opiate dependence at the molecular level, with perhaps a greater likelihood of successfully synthesizing new non-addicting exogenous opiates. ACKNOWLEDGEMENT I would like to thank Professor A. B. Baker for his constant encouragement.
